Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

Venice Servellita, Mary-Kate Morris, Alicia Sotomayor-Gonzalez, Amelia S. Gliwa, Erika Torres, Noah Brazer, Alicia Zhou, Katherine T. Hernandez, Madeline Sankaran, Baolin Wang, Daniel Wong, Candace Wang, Yueyuan Zhang, Kevin R Reyes, Dustin Glasner, Xianding Deng, Jessica Streithorst, Steve Miller, Edwin Frias, John Hackett Jr., Carl Hanson, Debra Wadford, Susan Philip, Scott Topper, Darpun Sachdev, View ORCID ProfileCharles Y. Chiu
doi: https://doi.org/10.1101/2021.08.19.21262139
Venice Servellita
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary-Kate Morris
3Viral and Rickettsial Disease Laboratory, California Department of Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia Sotomayor-Gonzalez
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelia S. Gliwa
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Torres
4Color Genomics, Inc., San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noah Brazer
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia Zhou
4Color Genomics, Inc., San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine T. Hernandez
5San Francisco Department of Public Health, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madeline Sankaran
5San Francisco Department of Public Health, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baolin Wang
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Wong
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Candace Wang
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yueyuan Zhang
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin R Reyes
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dustin Glasner
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianding Deng
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Streithorst
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Miller
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin Frias
6Abbott Laboratories, Abbott Park, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Hackett Jr.
6Abbott Laboratories, Abbott Park, Illinois, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Hanson
3Viral and Rickettsial Disease Laboratory, California Department of Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra Wadford
3Viral and Rickettsial Disease Laboratory, California Department of Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Philip
5San Francisco Department of Public Health, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Topper
4Color Genomics, Inc., San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darpun Sachdev
5San Francisco Department of Public Health, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Y. Chiu
1Department of Laboratory Medicine, University of California San Francisco, California, USA
2UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, California, USA
7Department of Medicine, University of California San Francisco, California, USA
8Innovative Genomics Institute, University of California Berkeley, Berkeley, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles Y. Chiu
  • For correspondence: charles.chiu@ucsf.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Associations between vaccine breakthrough cases and infection by SARS coronavirus 2 (SARS-CoV-2) variants have remained largely unexplored. Here we analyzed SARS-CoV-2 whole-genome sequences and viral loads from 1,373 persons with COVID-19 from the San Francisco Bay Area from February 1 to June 30, 2021, of which 125 (9.1%) were vaccine breakthrough infections. Fully vaccinated were more likely than unvaccinated persons to be infected by variants carrying mutations associated with decreased antibody neutralization (L452R, L452Q, E484K, and/or F490S) (78% versus 48%, p = 1.96e-08), but not by those associated with increased infectivity (L452R and/or N501Y) (85% versus 77%, p = 0.092). Differences in viral loads were non-significant between unvaccinated and fully vaccinated persons overall (p = 0.99) and according to lineage (p = 0.09 – 0.78). Viral loads were significantly higher in symptomatic as compared to asymptomatic vaccine breakthrough cases (p < 0.0001), and symptomatic vaccine breakthrough infections had similar viral loads to unvaccinated infections (p = 0.64). In 5 cases with available longitudinal samples for serologic analyses, vaccine breakthrough infections were found to be associated with low or undetectable neutralizing antibody levels attributable to immunocompromised state or infection by an antibody-resistant lineage. These findings suggest that vaccine breakthrough cases are preferentially caused by circulating antibody-resistant SARS-CoV-2 variants, and that symptomatic breakthrough infections may potentially transmit COVID-19 as efficiently as unvaccinated infections, regardless of the infecting lineage.

Competing Interest Statement

C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and receives research support from Abbott Laboratories, Inc. E.F. and J.H.,Jr. are employees and shareholders of Abbott Laboratories. E.T., A.Z., and S.T. are employees of Color Genomics. The other authors declare no competing interests.

Funding Statement

This work has been funded by US CDC Epidemiology and Laboratory Capacity (ELC) for Infectious Diseases Grant 6 NU50CK000539 to the California Department of Public Health (M-K.M., C.H., D.A.W.), the Innovative Genomics Institute (IGI) at UC Berkeley and UC San Francisco (C.Y.C.), National Institutes of Health grant R33AI129455 (C.Y.C.), US Centers for Disease Control and Prevention contract 75D30121C10991 (C.Y.C.), and Heluna Health/California Department of Public Health contract 5NU50CK000539‐01‐12 (C.Y.C.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Remnant nasopharyngeal and/or oropharyngeal (NP/OP) samples and plasma samples from laboratory confirmed SARS-CoV-2 positive patients were retrieved from the UCSF Clinical Laboratories and stored in a biorepository until processed. Remnant samples were biobanked and retrospective medical chart review for relevant clinical and demographic metadata were performed under a waiver of consent and according to protocols approved by the UCSF Institutional Review Board (protocol number 10-01116, 11-05519). De-identified samples from community COVID-19 testing were obtained from Color Genomics Laboratory as part of a research collaboration. Vaccine breakthrough data corresponding to the de-identified samples from Color Genomics were obtained from the San Francisco Department of Public Health. Approval for sequencing and analysis of these de-identified samples and metadata was obtained from the UCSF Institutional Review Board (protocol number 11-05519).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data Availability Assembled SARS-CoV-2 genomes in this study were uploaded to GISAID (accession numbers in Supplementary Table S2) and can be visualized in NextStrain. Viral genomes were also submitted to the National Center for Biotechnology Information (NCBI) GenBank database (accession numbers pending). Raw sequence data were submitted to the Sequence Read Archive (SRA) database. (BioProject accession number PRJNA722044 and umbrella BioProject accession number PRJNA171119). Code Availability FASTA files and scripting code for data analyses are available in a Zenodo data repository (https://doi.org/10.5281/zenodo.5207242).

https://doi.org/10.5281/zenodo.5207242

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Venice Servellita, Mary-Kate Morris, Alicia Sotomayor-Gonzalez, Amelia S. Gliwa, Erika Torres, Noah Brazer, Alicia Zhou, Katherine T. Hernandez, Madeline Sankaran, Baolin Wang, Daniel Wong, Candace Wang, Yueyuan Zhang, Kevin R Reyes, Dustin Glasner, Xianding Deng, Jessica Streithorst, Steve Miller, Edwin Frias, John Hackett Jr., Carl Hanson, Debra Wadford, Susan Philip, Scott Topper, Darpun Sachdev, Charles Y. Chiu
medRxiv 2021.08.19.21262139; doi: https://doi.org/10.1101/2021.08.19.21262139
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California
Venice Servellita, Mary-Kate Morris, Alicia Sotomayor-Gonzalez, Amelia S. Gliwa, Erika Torres, Noah Brazer, Alicia Zhou, Katherine T. Hernandez, Madeline Sankaran, Baolin Wang, Daniel Wong, Candace Wang, Yueyuan Zhang, Kevin R Reyes, Dustin Glasner, Xianding Deng, Jessica Streithorst, Steve Miller, Edwin Frias, John Hackett Jr., Carl Hanson, Debra Wadford, Susan Philip, Scott Topper, Darpun Sachdev, Charles Y. Chiu
medRxiv 2021.08.19.21262139; doi: https://doi.org/10.1101/2021.08.19.21262139

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)